Evofem Biosciences Inc. [EVFM] stock Initiated by Piper Sandler analyst, price target now $11

Must read

Evofem Biosciences Inc. [NASDAQ: EVFM] gained 1.92% or 0.06 points to close at $3.19 with a heavy trading volume of 2698241 shares. The company report on August 4, 2020 that Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update.

– Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -.

– Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea on Track for Q4 2020 Initiation -.

It opened the trading session at $3.13, the shares rose to $3.23 and dropped to $3.07, the range by which the price of stock traded the whole day. The daily chart for EVFM points out that the company has recorded -46.74% loss over the past six months. However, it is still -16.85% lower than its most recent low trading price.

If we look at the average trading volume of 4.08M shares, EVFM reached to a volume of 2698241 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Evofem Biosciences Inc. [EVFM]:

Piper Sandler have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on June 08, 2020. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on October 16, 2019, representing the official price target for Evofem Biosciences Inc. stock.

The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.16 The Price to Book ratio for the last quarter was 2.68, with the Price to Cash per share for the same quarter was set at 1.58.

Trading performance analysis for EVFM stock

Evofem Biosciences Inc. [EVFM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.59. With this latest performance, EVFM shares gained by 10.00% in over the last four-week period, additionally sinking by -46.74% over the last 6 months – not to mention a drop of -35.81% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 58.85, with the RSI for the last a single of trading hit 62.73, and the three-weeks RSI is set at 51.19 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 3.00, while it was recorded at 3.05 for the last single week of trading, and 4.81 for the last 200 days.

Evofem Biosciences Inc. [EVFM]: A deeper dive into fundamental analysis

When it comes to the capital structure of this company, Evofem Biosciences Inc. [EVFM] has a Total Debt to Total Equity ratio set at 1.26. Additionally, EVFM Total Debt to Total Capital is recorded at 1.24, with Total Debt to Total Assets ending up at 0.70.

Reflecting on the efficiency of the workforce at the company, Evofem Biosciences Inc. [EVFM] managed to generate an average of -$1,510,057 per employee.Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.10.

Evofem Biosciences Inc. [EVFM]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Evofem Biosciences Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVFM.

An analysis of insider ownership at Evofem Biosciences Inc. [EVFM]

There are presently around $202 million, or 39.40% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: INVESCO LTD. with ownership of 12,670,975, which is approximately 6.595% of the company’s market cap and around 2.00% of the total institutional ownership; WOODFORD INVESTMENT MANAGEMENT LTD, holding 12,496,222 shares of the stock with an approximate value of $39.86 million in EVFM stocks shares; and LINK FUND SOLUTIONS LTD, currently with $29.15 million in EVFM stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 71 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 15,906,359 shares. Additionally, 98 investors decreased positions by around 14,136,101 shares, while 12 investors held positions by with 33,412,036 shares. The mentioned changes placed institutional holdings at 63,454,496 shares, according to the latest SEC report filing. EVFM stock had 30 new institutional investments in for a total of 5,849,706 shares, while 56 institutional investors sold positions of 2,752,566 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam